SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* SIGMA TAU INTERNATIONAL SA (Last) (First) (Middle) 18 AVENUE DE LA PORTE NEUVE (Street) LUXEMBOURG N4 L-2227 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol QUESTCOR PHARMACEUTICALS INC [ QSC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/12/2004
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, no par value per share								8,643,397	D
Common Stock, no par value per share								1,756,781	I	Shares directly held by Claudio Cavazza.(1)
Common Stock, no par value per share								1,756,782	I	Shares directly held by Paolo Cavazza.(1)
Common Stock, no par value per share								1,265,822	I	Shares underlying the Warrants held by Defiante Farmaceutica L.d.A.(1)
Common Stock, no par value per share	01/12/2004		P		759,493	A	$0.644	759,493	I	Shares directly held by Defiante Farmaceutica L.d.A.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant representing the right to buy Common Stock	$1.7	01/12/2004		S			759,493	03/15/2002	03/15/2006	Common Stock, no par value per share	759,493	$0.07	1,265,822	I	The Warrants are held by Defiante Farmaceutica L.d.A.(1)

1. Name and Address of Reporting Person* SIGMA TAU INTERNATIONAL SA (Last) (First) (Middle) 18 AVENUE DE LA PORTE NEUVE (Street) LUXEMBOURG N4 L-2227 (City) (State) (Zip)

1. Name and Address of Reporting Person* SIGMA TAU FINANZIARIA SPA (Last) (First) (Middle) VIA SUDAFRICA 20 144 (Street) ROME ITALY (City) (State) (Zip)

1. Name and Address of Reporting Person* DEFIANTE FARMACEUTICA LDA (Last) (First) (Middle) RUA DOS FERREIROS,260 (Street) FUNCHAL MADEIRA S1 9000-082 (City) (State) (Zip)

1. Name and Address of Reporting Person* CAVAZZA CLAUDIO (Last) (First) (Middle) VIA SUDAFRICA 20 (Street) ROME ITALY L6 00000 (City) (State) (Zip)

1. Name and Address of Reporting Person* CAVAZZA PAOLO (Last) (First) (Middle) VIA TESSERETE, 10 (Street) LUGANO V8 V8 (City) (State) (Zip)

1. Name and Address of Reporting Person* APTAFIN S P A (Last) (First) (Middle) VIALE SHAKESPEARE 47 (Street) ROME L6 00144 (City) (State) (Zip)

Explanation of Responses:

1. Sigma-Tau Finanziaria S.p.A. owns 100% of the capital stock of Sigma-Tau International S.A. (f/k/a Sigma-Tau Finance Holding S.A.) and 58% of the capital stock of Defiante Farmaceutica L.d.A. Sigma-Tau International S.A. owns 42% of the capital stock of Defiante Farmaceutica L.d.A. Claudio Cavazza owns, directly and indirectly, 60% of Sigma-Tau Finanziaria S.p.A. and Paolo Cavazza owns, directly and indirectly, 40% of Sigma-Tau Finanziaria S.p.A. Paolo Cavazza also owns, directly and indirectly, 100% of Aptafin S.p.A.

Remarks:

The 759,493 shares of Common Stock, no par value per share, were purchased from Questcor Pharmaceuticals Inc. for total consideration of $489,113.51, consisting of $435,949.00 in cash and the surrender of 759,493 warrants held by Defiante Farmaceutica L.d.A. (which were valued at $53,164.51 upon surrender).

	Maurizio Terenzi, Attorney-in-fact for Sigma-Tau International S.A.	01/14/2003
	Maurizio Terenzi, Attorney-in-fact for Sigma-Tau Finanziari S.p.A.	01/14/2003
	Maurizio Terenzi, Attorney-in-fact for Defiante Farmaceutica L.D.A.	01/14/2003
	Maurizio Terenzi, Attorney-in-fact for Claudio Cavazza	01/14/2003
	Maurizio Terenzi, Attorney-in-fact for Paolo Cavazza	01/14/2003
	Maurizio Terenzi, Attorney-in-fact for Aptafin S.p.A.	01/14/2003
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.